Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.

Cancer medicine - 1 Aug 2022

Chen Zhuxing, Liu Liping, Zhu Feng, Cai Xiuyu, Zhao Yi, Liang Peng, Ou Limin, Zhong Ran, Yu Ziwen, Li Caichen, Li Jianfu, Xiong Shan, Feng Yi, Cheng Bo, Liang Hengrui, Xie Zhanhong, Liang Wenhua, He Jianxing

Abstract excerpt

To reveal the correlation of dynamic serum tumor markers (STMs) and molecular features of epidermal growth factor receptor-mutated (EGFR-mutated) lung cancer during targeted therapy, we retrospectively reviewed 303 lung cancer patients who underwent dynamic STM tests [neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153), the soluble...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Carbohydrates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Keratin-19

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35543090
DOI: 10.1002/cam4.4676
PMCID: PMC9385589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.PMID 35543090Read ↗

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.Semantic proximity Read ↗

The Prognostic and Predictive Value of Pretreatment Serum Tumor Markers in Lung Adenocarcinoma with Different EGFR StatusSemantic proximity Read ↗

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.Semantic proximity Read ↗

Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.Semantic proximity Read ↗

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.Semantic proximity Read ↗

Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.Semantic proximity Read ↗

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs.Semantic proximity Read ↗

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.